Search

Your search keyword '"Baroni, Lorena V."' showing total 17 results
Start Over Author "Baroni, Lorena V."
17 results on '"Baroni, Lorena V."'

7. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q

Author

Baroni, Lorena V, primary, Sundaresan, Lakshmikirupa, additional, Heled, Ayala, additional, Coltin, Hallie, additional, Pajtler, Kristian W, additional, Lin, Tong, additional, Merchant, Thomas E, additional, McLendon, Roger, additional, Faria, Claudia, additional, Buntine, Molly, additional, White, Christine L, additional, Pfister, Stefan M, additional, Gilbert, Mark R, additional, Armstrong, Terri S, additional, Bouffet, Eric, additional, Kumar, Sachin, additional, Taylor, Michael D, additional, Aldape, Kenneth D, additional, Ellison, David W, additional, Gottardo, Nicholas G, additional, Kool, Marcel, additional, Korshunov, Andrey, additional, Hansford, Jordan R, additional, and Ramaswamy, Vijay, additional

Published
2021
Full Text
View/download PDF

8. RARE-50. TREATMENT RESPONSE OF CNS HIGH-GRADE NEUROEPITHELIAL TUMORS WITH MN1 ALTERATION

Author

Baroni, Lorena V, primary, Rugilo, Carlos, additional, Lubieniecki, Fabiana, additional, Sampor, Claudia, additional, Freytes, Candela, additional, Nobre, Liana, additional, Hansford, Jordan R, additional, Malalasekera, Vajiranee S, additional, Zapotocky, Michal, additional, Dodgshun, Andrew, additional, Ramaswamy, Vijay, additional, and Alderete, Daniel, additional

Published
2020
Full Text
View/download PDF

9. Treatment response of CNS high‐grade neuroepithelial tumors with MN1 alteration

Author

Baroni, Lorena V., primary, Rugilo, Carlos, additional, Lubieniecki, Fabiana, additional, Sampor, Claudia, additional, Freytes, Candela, additional, Nobre, Liana, additional, Hansford, Jordan R., additional, Malalasekera, Vajiranee S., additional, Zapotocky, Michal, additional, Dodgshun, Andrew, additional, Martinez, Ofelia Cruz, additional, La Madrid, Andres Morales, additional, Lavarino, Cinzia, additional, Suñol, Mariona, additional, Rutkowski, Stefan, additional, Schuller, Ulrich, additional, Bouffet, Eric, additional, Ramaswamy, Vijay, additional, and Alderete, Daniel, additional

Published
2020
Full Text
View/download PDF

10. Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen

Author

Baroni, Lorena V, primary, Sampor, Claudia, additional, Gonzalez, Adriana, additional, Lubieniecki, Fabiana, additional, Lamas, Gabriela, additional, Rugilo, Carlos, additional, Bartels, Ute, additional, Heled, Ayala, additional, Smith, Kyle S, additional, Northcott, Paul A, additional, Bouffet, Eric, additional, Alderete, Daniel, additional, and Ramaswamy, Vijay, additional

Published
2020
Full Text
View/download PDF

11. Bevacizumab for NF2‐associated vestibular schwannomas of childhood and adolescence

Author

Renzi, Samuele, primary, Michaeli, Orli, additional, Salvador, Hector, additional, Alderete, Daniel, additional, Ponce, Nicolas Fernandez, additional, Zapotocky, Michal, additional, Hansford, Jordan R., additional, Malalasekera, Vajiranee S., additional, Toledano, Helen, additional, Maguire, Bryan, additional, Bouffet, Eric, additional, Ramaswamy, Vijay, additional, and Baroni, Lorena V., additional

Published
2020
Full Text
View/download PDF

12. Bevacizumab for pediatric radiation necrosis

Author

Baroni, Lorena V, primary, Alderete, Daniel, additional, Solano-Paez, Palma, additional, Rugilo, Carlos, additional, Freytes, Candela, additional, Laughlin, Suzanne, additional, Fonseca, Adriana, additional, Bartels, Ute, additional, Tabori, Uri, additional, Bouffet, Eric, additional, Huang, Annie, additional, Laperriere, Normand, additional, Tsang, Derek S, additional, Sumerauer, David, additional, Kyncl, Martin, additional, Ondrová, Barbora, additional, Malalasekera, Vajiranee S, additional, Hansford, Jordan R, additional, Zápotocký, Michal, additional, and Ramaswamy, Vijay, additional

Published
2020
Full Text
View/download PDF

14. TERAPIAS DIRIGIDAS CON INHIBIDORES DEL BRAF EN GLIOMAS PEDIÁTRICOS DE ALTO Y BAJO GRADO CON LA MUTACIÓN BRAFV600E. EXPERIENCIA DEL HOSPITAL PROF. DR. JUAN P. GARRAHAN.

Author

WARRINER, ERIC, FERNÁNDEZ PONCE, NICOLÁS, FREYTES, CANDELA, SAMPOR, CLAUDIA, OLLER, AGUSTINA, RUGILO, CARLOS, LUBIENIECKI, FABIANA, VAZQUEZ, VALERIA, ALDERETE, DANIEL, and BARONI, LORENA V.

Abstract

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

15. Anterior Segment Invasion in Retinoblastoma

Author

Baroni, Lorena V., primary, Sampor, Claudia, additional, Fandiño, Adriana, additional, Solernou, Veronica, additional, Demirdjian, Graciela, additional, de Davila, Maria T.G., additional, and Chantada, Guillermo L., additional

Published
2014
Full Text
View/download PDF

17. [Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].

Author

Warriner E, Fernández Ponce N, Freytes C, Sampor C, Oller A, Rugilo C, Lubieniecki F, Vazquez V, Alderete D, and Baroni LV

Subjects
Child, Hospitals, Humans, Mutation, Proto-Oncogene Mas, Retrospective Studies, Glioma drug therapy, Glioma genetics, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics
Abstract

The BRAFV600E point mutation plays a key role in the tumorigenesis of many gliomas. Inhibiting its product is part of the innovative therapies emerging in recent years. Knowing the role of these treatments is essential. The aim of this experience was to describe the clinical-radiological response of pediatric BRAFV600E mutated gliomas treated with BRAF inhibitors. To this end, a descriptive and retrospective study was performed in patients under 16 years of age with BRAFV600E gliomas, who received vemurafenib or dabrafenib at Hospital Garrahan. Thirteen patients treated in the last 7 years were included: 9 were low-grade and 4 high-grade gliomas. The median age at diagnosis was 8.6 years (0.89-14.04) and at start of targeted therapy was 11.62 years (3.64-15.42). All patients had previously a surgical procedure, and 12/13 had received another therapy prior BRAF inhibition: 11 chemotherapy (in one case, up to 4 different protocols) and 4 radiotherapy. Under targeted therapy, tumour response was obtained in 10 patients (size reduction equal to or greater than 25%), and best response was observed in the first 6 months of treatment in 7 children. Four patients progressed under treatment (all high-grade gliomas) and 2 progressed shortly after stopping the inhibitor (both low-grade gliomas). Five patients had grade 3-4 toxicity, with subsequent full recovery. A good and sustained clinical-radiological response, with acceptable tolerance, is described in patients with BRAFV600E mutated low-grade gliomas treated with BRAFV600E inhibitors. In contrast, the response in patients with high-grade gliomas was intermediate and of short duration, with early tumour progression.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results